Treating mucostasis in CF infants and adults with hypertonic saline and dornase alfa has shown clinical benefit and pre-clinical studies of agents that disrupt disulfide bonds in mucins are promising (McCoy et al., 1996; Donaldson et al., 2006; Ehre et al., 2019). The gene discussed is DNASE1; the disease is cystic fibrosis.